In yesterday’s Wall Street session, TRACON Pharmaceuticals Inc (NASDAQ:TCON) shares traded at $0.39, up 7.86% from the previous session.
TCON stock price is now 82.68% away from the 50-day moving average and 57.73% away from the 200-day moving average. The market capitalization of the company currently stands at $17.72M.
With the price target maintained at $14, BTIG Research recently Upgraded its rating from Neutral to Buy for TRACON Pharmaceuticals Inc (NASDAQ: TCON). On February 10, 2021, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $24, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, THEUER CHARLES, President and CEO bought 47,000 shares of the company’s stock on Apr 27 ’23. The stock was bought for $35,250 at an average price of $0.75. Upon completion of the transaction, the President and CEO now directly owns 399,417 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 26 ’23, President and CEO THEUER CHARLES bought 3,999 shares of the business’s stock. A total of $2,639 was incurred on buying the stock at an average price of $0.66. This leaves the insider owning 352,417 shares of the company worth $0.14 million. A total of 9.23% of the company’s stock is owned by insiders.
During the past 12 months, TRACON Pharmaceuticals Inc has had a low of $0.13 and a high of $2.19. The fifty day moving average price for TCON is $0.2133 and a two-hundred day moving average price translates $0.2470 for the stock.
The latest earnings results from TRACON Pharmaceuticals Inc (NASDAQ: TCON) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0.01, beating analysts’ expectations of -$0.08 by 0.09. This compares to -$0.30 EPS in the same period last year. The net profit margin was -29.79% and return on equity was -1277.01% for TCON.
